IMM 1.47% 34.5¢ immutep limited

Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022, page-13

  1. 25,459 Posts.
    lightbulb Created with Sketch. 1387
    Poster Display session (ID 9)

    171P - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer (ID 179)

    Presentation Number
    171P
    Lecture Time
    12:15 - 12:15
    Speakers
    Session Name
    Poster Display session (ID 9)
    Room
    Exhibition area
    Date
    Wed, 04.05.2022
    Time
    12:15 - 13:00

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
34.5¢
Change
0.005(1.47%)
Mkt cap ! $501.1M
Open High Low Value Volume
34.0¢ 36.0¢ 33.5¢ $2.184M 6.253M

Buyers (Bids)

No. Vol. Price($)
5 156342 34.5¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 107414 4
View Market Depth
Last trade - 16.10pm 18/09/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.